VALIRX ENDORSES THE GOVERNMENT’S NEW NHS STRATEGY
“Through the application of novel personalised therapeutic and early diagnostic therapies”
London, UK., 09 January 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to endorse the Government’s new NHS Long Term Plan (www.longtermplan.nhs.uk) to improve the quality of patient care and health outcomes.
ValiRx’s stated ambition, for some time, has been the personalisation of novel therapeutics and through genetic mapping, to facilitate the early detection of cancers.
This ambition has long been at the forefront of much of ValiRx’s work in the oncology arena and it is excellent news that the Government is now actively discussing and championing these therapeutic and diagnostic approaches.
With ValiRx currently developing precision therapeutics for hormone induced cancers coupled with new technology for early detection, the Company is delighted to be among the front runners contributing to this government and NHS-led initiative.
Dr Satu Vainikka, CEO of ValiRx, commented: “ValiRx is an innovative biotechnology company developing novel and improved therapeutics, both in the UK and globally. The Government’s recently announced ten-year plan of investing in the prevention and early diagnosis of diseases, such as certain neurological, mental and oncological diseases, is a policy that we have been following and striving to address for some time”.